Volume 2015 Supplement 1
Pseudoaldosteronism due to mutation of SCNN1A gene: a case report
© Ngoc et al; licensee BioMed Central Ltd. 2015
Published: 28 April 2015
Pseudohypoaldosteronism type 1 (PHA1) is a rare inherited disease characterized by resistance to the actions of aldosterone. It was first described in 1958 by Cheek and Perry, and common clinical manifestations include salt wasting, hyperkalaemia, metabolic acidosis and elevated plasma aldosterone levels in the neonatal period.
To describe clinical characteristics, laboratory features and management of one Vietnamese patient with pseudohypoaldosteron.
Subject and methods
Clinical features, biochemical finding, mutation analysis and management in a 1 months-old-boy was studied. Based on analysis of this patient’s clinical symptoms associated with biochemical examination, the urinary steroid metabolomics analysis was performed using gas chromatography spectrometry and mutation analysis of SCNN1A was performed using PCR & direct sequencing.
Patient is the first child normal delivery with the gestation age of 41 weeks, birth weight of 3200 g, and onset of the disease at 7 days of age. He presented with lost weight, dehydration without vomit, diarrhea or hyperpigmentation. He was admitted with the features of cyanosis, allorhythmic, electrolyte imbalance with sodium of 119 mmol/l, potassium of 7.4 mmol/l. Investigation show pH 7.26, PCO2 34 mmHg, PO2 110 mmHg, HCO-3 18mmol/l, BE -10, plasma 17OHP level: 2,4 ng/ml, testosterone level: 1.94 nmol/l, Cortisol 8am: 2662,8 pmol/l, Ure 7.4 mmol/l, Creatinine 44.2 umol/l, Glucose 4.8 mmol/l. the urine steroid metabolomics analysis showed extensive excretion of aldosterone ID-ISTD1 of 1157.41 µg/l. Novel homozygous mutation (c.1668C>A; p.S556R) of SCNN1A gene was identified in the proband. He was treated with florinef of 0.1 mg/kg/day for electrolyte balance. He had complication of intestinal perforation and died due to infection. In conclusions, PHA1 causes severe hyponatremia, metabolic acidosis, and life-threatening hyperkalemia, with normal 17-a-hydroxyprogesterone levels and high excretion of aldosterone levels
Written informed consent was obtained from the patient's parent or guardian for publication of this Case report (and any accompanying images). A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.